Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
652.00    12.00 (1.88%)
Bid:
644.00
Ask:
660.00
Spread: 16.00 (2.484%)
Market Cap: £219.22m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

Exercise of Options & TVR

30 Apr 2026 14:41

RNS Number : 6477C
Avingtrans PLC
30 April 2026
 

30 April 2026

Avingtrans Plc

("Avingtrans", the "Company", or the "Group")

Exercise of Options & TVR

Avingtrans plc (AIM: AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, announces that on 30 April 2026, the Company was notified of the exercise of 352,750 options over ordinary shares of 5p each in the Company ("Ordinary Shares") by Steve McQuillan, Chief Executive Officer, Stephen King, Chief Financial Officer, Austen Adams, Chief Operating Officer and certain non-PDMRs.

PDMR

Role

Options exercised

Beneficial interest in Ordinary Shares following the transactions

Resulting percentage holding of enlarged total voting rights held

Steve McQuillan

Chief Executive Officer

120,000

828,675

2.46%

Stephen King

Chief Financial Officer

115,000

688,614

2.05%

Austen Adams

Chief Operating Officer

110,000

173,301

0.52%

 

Issue of Equity

Application has been made for the admission to trading on AIM for the 352,750 new Ordinary Shares ("Admission"). It is expected that Admission will become effective on 7 May 2026.

Total Voting Rights

Following the issue of the 352,750 new Ordinary Shares, the Company will have a total of 33,622,072 Ordinary Shares in issue. The Company does not hold any shares in Treasury. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules

 

Enquiries:

Avingtrans plc

01354 692 391

Roger McDowell, Chairman

Steve McQuillan, Chief Executive Officer

Stephen King, Chief Financial Officer

 

Singer Capital Markets (Nominated Adviser and Broker)

020 7496 3000

Sara Hale

 

Alex Bond

 

Carl Diebitsch

 

IFC Advisory (Financial PR)

 020 3934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

1. Steve McQuillan

2. Stephen King

3. Austen Adams

2

 

Reason for the notification

 

a)

 

Position/status

 

 

1. Chief Executive Officer

2. Chief Financial Officer

3. Chief Operating Officer

 

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Avingtrans PLC

b)

 

LEI

 

 

213800ZZ96CKPI423E86

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5p each

Identification code

ISIN: GB0009188797

 

b)

 

Nature of the transaction

 

 

Exercise of options pursuant to the CSOP

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

410p

120,000

2.

410p

115,000

3.

410p

110,000

 

 

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

 

30 April 2026

f)

 

Place of the transaction

 

 

Off market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEADLEDDPKEFA
Date   Source Headline
19th May 202610:20 amRNSHolding(s) in Company
14th May 202612:26 pmRNSHolding(s) in Company
12th May 20267:00 amRNSAdaptix receives CE Certification
6th May 20264:28 pmRNSHolding(s) in Company
30th Apr 20262:42 pmRNSHolding(s) in Company
30th Apr 20262:41 pmRNSExercise of Options & TVR
24th Apr 20262:54 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSStrong Nuclear Orders for Avingtrans
26th Mar 20267:00 amRNS-RScientific Magnetics Ships 20th Quantum Magnet
4th Mar 20267:00 amRNSHolding(s) in Company
25th Feb 20267:00 amRNSInterim Results
12th Feb 202611:49 amRNSHolding(s) in Company
6th Feb 202610:24 amRNSHolding(s) in Company
27th Jan 20265:42 pmRNSExercise of Options & TVR
21st Jan 20267:00 amRNSTrading Update and Notice of Results
12th Jan 20265:13 pmRNSIssue of Share Options
12th Jan 20267:00 amRNS-RMedical & Industrial Imaging Division Appointment
8th Dec 20252:34 pmRNSNotification of Major Holdings
27th Nov 20251:59 pmRNSResult of AGM - Board Appointment
14th Nov 20258:38 amRNSExercise of Options & PDMR Dealings
10th Nov 20257:00 amRNSAdaptix receives FDA 510(K) clearance
1st Oct 20254:52 pmRNSExercise of Options & Total Voting Rights
1st Oct 20253:32 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSAppointment of Medical Division CEO
24th Sep 20257:00 amRNSPreliminary results for the year ended 31 May 2025
11th Sep 20258:00 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSHayward Tyler Secures $16m Nuclear Contracts
28th Aug 20257:00 amRNSBooth Industries secures £8.5m HS2 & TfL contracts
25th Jun 20257:00 amRNSTrading Update and Notice of Results
28th May 20257:00 amRNSTrading Update
26th Feb 20257:00 amRNSInterim Results
13th Feb 20257:00 amRNSBooth Industries secures £4.5m Contract
16th Jan 20257:00 amRNSTrading Update & Notice of Results
21st Nov 20244:09 pmRNSResult of AGM
24th Oct 20249:07 amRNSHolding(s) in Company
25th Sep 20247:00 amRNSPreliminary results for the year ended 31 May 2024
3rd Jul 20247:00 amRNSPDMR Dealings
19th Jun 20247:00 amRNSTrading Update and Notice of Results
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor
22nd Nov 20237:00 amRNSEmployee & PDMR Share Incentive Awards
16th Nov 20232:20 pmRNSResult of AGM
13th Nov 20237:00 amRNSHayward Tyler Contract Win
11th Oct 20237:00 amRNSContract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.